[Correlation between Chlamydia pneumoniae infection and chronic obstructive pulmonary disease].

OBJECTIVE: To investigate the correlation between Chlamydia pneumonia (Cpn) infection and chronic obstructive pulmonary disease (COPD). METHODS: 82 patients with acute exacerbation COPD (AE-COPD) or stabilized COPD patients at outpatient visits, in the People's Hospital of Jiangyin city from Aug. 2010 to May 2012, together with 46 cases having stationary phase COPD and 38 healthy volunteers as control group, were involved in this study. Patients were bled 2 ml, on the next day of hospitalization while patients at emergency room were bled 2 ml immediately, but bled again on the 15(th) day. Serum was separated through cryopreservation and the Cpn antibodies (IgG, IgM and IgA antibodies) were detected, under micro-immunofluorescence. RESULTS: In terms of IgG in the three groups, the positive rates did not show significant differences (P > 0.05) but the GMT of the IgG in the AE-COPD group was significantly higher (P < 0.01) than that in the control group. IgA positive rate among the three groups; AE-COPD appeared the highest. There was no significant difference between the AE-COPD group and stationary phase COPD group (P > 0.05), however, there were significant differences between the AE-COPD group, the stationary phase COPD group and the control group (P < 0.01). In terms of GMT of IgA in the three groups, there was significant difference between the AE-COPD group and stationary phase COPD group (P > 0.05), but with significant difference between the AE-COPD group and the control group (P > 0.01). There was significant difference between stationary phase COPD group and the control group (P > 0.05). When comparing both the rates of acute infection and chronic infection on the AE-COPD groups with the control group, there appeared significant differences (P < 0.05, P < 0.01). When comparing the acute and chronic infection between the stationary phase COPD group and the control group, the rate of acute infection did not show significant difference (P > 0.05) while the chronic infection rate appear to have had significant difference (P < 0.01). CONCLUSION: Cpn infection seemed to be closely related to the development of COPD.

Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.

PURPOSE: This phase II study is performed to evaluate the safety, efficacy and tolerability of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: All patients were treated with the combination of docetaxel 35 mg/m(2) by IV infusion over 30-60 min weekly, on days 1, 8, and 15, for 3 weeks followed by 1 week of rest, with intravenous carboplatin (AUC 6) administered immediately afterward on day 1. Cycles were repeated every 28 days. RESULTS: Forty-seven (95.9%) of the 49 patients were assessable for response, one case of complete response and 17 cases of partial response were confirmed, giving an overall response rate of 36.7% (95% CI 23.2-50.2%). The median time to progression and overall survival (OS) for all patients were 5.2 months (95% CI 4.1-6.3 months) and 10.4 months (95% CI 7.3-13.5 months), respectively. The estimate of OS at 12 months was 37.6% (95% CI 24.0-51.2%). The most severe hematologic adverse event was anemia, which occurred with grade 3/4 intensity in 7 (14.9%) patients. Neutropenia occurred with grade 3 intensity in 4 (8.5%) patients. However, no grade 4 neutropenia was observed. Grade 3 nausea/vomiting, diarrhea, asthenia, nail changes, and skin reaction were observed in 6 (12.8%), 3 (6.4%), 2 (4.3%), 2 (4.3%) and 1 (2.1%) patients. Yet, no grade 4 non-hematologic toxicity was observed. CONCLUSIONS: The combination of carboplatin with weekly docetaxel is a tolerated treatment modality with encouraging activity and survival outcome in previously untreated patients with advanced NSCLC.